Lexicon Pharmaceuticals, Inc.

We are so excited to support this incredible event put on by Taking Control Of Your Diabetes (TCOYD). We hope to see some of you there!

Lexicon’s Q2 2025 financial results are now available. Learn more about our latest business updates in our press release: https://lnkd.in/gjQgMM7B

We’re proud to have been corporate sponsors of the American Society for Preventive Cardiology (ASPC) conference – an event focused on pioneering advancements in cardiovascular care.    At Lexicon, we’re dedicated to improving outcomes for those with hypertrophic cardiomyopathy (HCM) and thoroughly enjoyed connecting with others dedicated to advancing research, treatment and care for heart health. #ASPC2025 

Diabetic peripheral neuropathy (DPN) is a type of nerve damage that impacts millions of patients with diabetes.      Affecting patients’ legs and feet, followed by hands and arms, this damage can be painful, significantly affecting physical abilities and mobility, even impacting simple tasks like walking.    Despite prevalence expected to rise, no new therapies for neuropathic pain have been made available to patients in more than 20 years.     Our goal is to change that. At Lexicon, we’re advancing a novel, non-opioid therapy which uniquely inhibits neurotransmitters involved in pain signaling.    #DiabeticPeripheralNeuropathy #LearnWithLexicon 

On August 6, Lexicon will report our second quarter financial results along with a comprehensive business update. Conference call details can be found here: https://lnkd.in/gPq9rkJP

Over the weekend, Lexicon attended the American Society of Pain and Neuroscience ASPN 2025 Congress, presenting a poster on the patient experience of those living with diabetic peripheral neuropathic pain (DPNP).    DPNP is a chronic, painful condition impacting millions of people with diabetes. 

Today, our Vice President of Clinical Development, Suma Gopinathan, PhD, is participating on a keynote panel discussing the value of AI and its role in driving innovation.     At Lexicon, we understand that the power of AI lies in the consistency and integrity of data via our Genome5000™ program. This unique program is comprised of 1 Petabyte of consistent and high integrity proprietary data with a history of 10 clinical stage assets identified. The strength and potential power of this data is expanded by the advanced AI capabilities being developed across the industry. 

Over the past year, our CEO Mike Exton, PhD's vision and leadership have been instrumental in driving forward our company and our mission to innovate on behalf of patients. This week, we celebrate his one-year anniversary at Lexicon.   Read more about Mike's journey at Lexicon in an article he recently penned reflecting on his first year with the company.

Following the recent American Diabetes Association (ADA) conference, our Senior Medical Director, Belinda Hardin, PharmD, spoke with Managed Healthcare Executive on a recently presented analysis regarding the risks of hypoglycemia for individuals living with Type 1 diabetes.    Severe hypoglycemia, a potentially life-threatening low-blood-sugar condition, affects patients’ quality of life.   Read the full article: https://lnkd.in/gzTMsAB7

As a result of nerve damage in one’s hands and feet, patients with diabetic peripheral neuropathy (DPN) often experience tingling or burning sensations, sharp pains, or extreme sensitivity to touch. For some, even the touch of socks or bed sheets can be painful. Yet for many, current therapies don’t provide adequate relief. These patients deserve better. At Lexicon, we’re committed to redefining the standard of care for those with DPN and bringing forward a novel, non-opioid therapy to help those living in pain. #DiabeticPeripheralNeuropathy #LearnWithLexicon